Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models.

Mol Cancer Ther · 2022 · PMC9716246 · PMID 36198025

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Following ABX196 administration, there was a significant increase in the percentage of iNKT cells expressing CD1d markers (CD45 + /CD3 + /CD19 − cells) versus control in spleen ( P < 0.05), while the increase did not reach statistical significance versus control in TDLNs and tumoral tissue ( Fig. 4B ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.